公开(公告)号：US20240393334A1

公开(公告)日：2024-11-28

申请号：US18743218

申请日：2024-06-14

Applicant: Abbott Laboratories

Inventor： Tony K. Lee ,  Peter J. Karabatsos ,  Andrew S. Schapals ,  Antti Virtanen ,  Beth McQuiston ,  Craig A. Jeffrey ,  Alison Taylor ,  Raj Chandran ,  Jaime Marino ,  Saul Datwyler

IPC: G01N33/573 ,  A61B5/15 ,  G01N33/68 ,  G01N33/76 ,  G01N33/78

Abstract: Disclosed herein are systems and methods for determining ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof in a blood sample obtained from a subject. Also disclosed herein are systems and methods for determining CK-MB, β-hCG, thyroid stimulating hormone (TSH), homocysteine, free thyroxine (free T4) or any combinations thereof in a blood sample.

公开(公告)号：US12105100B2

公开(公告)日：2024-10-01

申请号：US17316257

申请日：2021-05-10

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Jaime Marino

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N33/6893 ,  G01N2800/28 ,  G01N2800/2871 ,  G01N2800/60

Abstract: Disclosed herein are methods of aiding in the diagnosis and evaluation of a subject that has sustained or may have sustained an injury to the head. For example, the present disclosure provides methods for aiding in the diagnosis and evaluation of a subject to determine whether the subject has sustained a traumatic brain injury (TBI) by detecting or measuring a combination of the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) in samples taken at various time points within 48 hours after the subject has sustained or may have sustained an injury to the head.

公开(公告)号：US12105098B2

公开(公告)日：2024-10-01

申请号：US17316267

申请日：2021-05-10

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul A. Datwyler ,  Raj Chandran

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  C12Y301/02015 ,  G01N2333/47 ,  G01N2333/916 ,  G01N2800/28 ,  G01N2800/2871 ,  G01N2800/52

Abstract: Disclosed herein are methods, and kits for use in said methods, that aid in the diagnosis and evaluation of a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed herein are methods, and kits for use in said methods, that aid in determining whether a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head would benefit from and thus receive an imaging procedure, such as MRI or head computerized tomography (CT) scan based on the levels of GFAP and/or UCH-L1. These methods involve detecting levels and changes in levels of GFAP and/or UCH-L1 in biological samples taken from a subject at time points within 48 hours after the subject has sustained or may have sustained an injury to the head.

公开(公告)号：US20240094226A1

公开(公告)日：2024-03-21

申请号：US18509717

申请日：2023-11-15

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Jaime Marino ,  Hongwei Zhang

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N2333/916 ,  G01N2333/948 ,  G01N2800/28 ,  G01N2800/50

Abstract: Disclosed herein are methods of determining whether a subject has a traumatic brain injury (TBI) by detecting levels of at least one biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a subject.

公开(公告)号：US11016105B2

公开(公告)日：2021-05-25

申请号：US16203373

申请日：2018-11-28

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Jaime Marino

IPC: G01N33/68

Abstract: Disclosed herein are methods of aiding in the diagnosis and evaluation of a subject that has sustained or may have sustained an injury to the head. For example, the present disclosure provides methods for aiding in the diagnosis and evaluation of a subject to determine whether the subject has sustained a traumatic brain injury (TBI) by detecting or measuring a combination of the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) in samples taken at various time points within 48 hours after the subject has sustained or may have sustained an injury to the head.

公开(公告)号：US20190242906A1

公开(公告)日：2019-08-08

申请号：US16213898

申请日：2018-12-07

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  C12Y301/02015 ,  G01N2333/47 ,  G01N2333/916 ,  G01N2800/28 ,  G01N2800/2871 ,  G01N2800/52

Abstract: Disclosed herein are methods, and kits for use in said methods, that aid in the diagnosis and evaluation of a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed herein are methods, and kits for use in said methods, that aid in determining whether a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head would benefit from and thus receive an imaging procedure, such as MRI or head computerized tomography (CT) scan based on the levels of GFAP and/or UCH-L1. These methods involve detecting levels and changes in levels of GFAP and/or UCH-L1 in biological samples taken from a subject at time points within 48 hours after the subject has sustained or may have sustained an injury to the head.

公开(公告)号：US20160022617A1

公开(公告)日：2016-01-28

申请号：US14775972

申请日：2014-03-14

Applicant: ABBOTT LABORATORIES

Inventor： Menghua Luo ,  Suzette Pereira ,  Neile Edens ,  Gerard Davis ,  Susan Gawel ,  Raj Chandran

IPC: A61K31/19 ,  G01N33/68

CPC classification number: A61K31/19 ,  G01N33/6893 ,  G01N2333/47 ,  G01N2333/4704 ,  G01N2333/575 ,  G01N2800/52

Abstract: Insulin resistance biomarkers and related methods of using the biomarkers are provided. The biomarkers may be blood biomarkers and include C-peptide, Insulin-Like Growth Factor-Binding Protein 2 (IGFBP-2), and Leptin. Also provided is a method of reducing the effect of prolonged physical inactivity on insulin resistance in a subject who is experiencing prolonged physical inactivity, or who is expected to experience prolonged physical inactivity in the near future.

Abstract translation: 提供了使用生物标志物的胰岛素抵抗生物标志物和相关方法。 生物标志物可以是血液生物标志物，包括C肽，胰岛素样生长因子结合蛋白2（IGFBP-2）和瘦蛋白。 还提供了一种减少长期身体不活动对经历长时间身体不活动的受试者或预期在不久的将来会经历长时间身体不活动的受试者的胰岛素抵抗的影响的方法。